-72%

est. 2Y upside i

HealthcareSeed

Subscription pharmacy for patients with chronic diseases

Rank

#4099

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

This equity opportunity presents a high-risk profile primarily due to intense incumbent competition and critical internal challenges, making substantial upside within a two-year timeframe unlikely despite the company's profitability.

Last updated: February 16, 2026

Bull (15%)+250%

Digi-Prex successfully differentiates its service, significantly increases market share despite intense competition, and secures a strong Series A funding round.

Base (30%)0%

The company maintains its niche and profitability with slow growth, but struggles to scale against dominant competitors, leading to a flat valuation.

Bear (55%)-90%

Digi-Prex fails to effectively compete with incumbents, struggles to raise further capital, or is acquired in a distressed sale, resulting in significant equity loss.

Est. time to liquidity~3.0 years

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.